The randomized controlled European Organisation for Research and Treatment of Cancer (EORTC) trial 22911 studied the effect of radiotherapy after prostatectomy in patients with adverse risk factors. Review pathology data of specimens from participants in this trial were analyzed to identify which factors predict increased benefit from adjuvant radiotherapy.
INTRODUCTION
Approximately 35% of patients undergoing a radical prostatectomy for their prostate cancer will experience biochemical recurrence within 10 years of surgery. [1] [2] [3] The most significant risk factors for biochemical recurrence after prostatectomy are high Gleason score, extraprostatic extension, seminal vesicle invasion, and a positive surgical margin. 4, 5 Both smaller nonrandomized studies [6] [7] [8] [9] and recently the large randomized controlled trial by the European Organisation for Research and Treatment of Cancer (EORTC) 10, 11 have demonstrated convincingly that radiotherapy immediately after prostatectomy in patients with adverse risk factors diminishes their risk of biochemical recurrence and improves local control of the disease. EORTC trial 22911 was initiated in 1992 as a multi-institutional phase III trial to test the hypothesis that immediate radiotherapy after prostatectomy of patients with a pT3N0M0 or prostatic adenocarcinoma with positive surgical margin improves their progression-free survival. Although a preliminary analysis of risk factors showed that patients with any adverse risk factor benefited from postoperative radiotherapy, the patients with positive surgical margins seemed to benefit most. 
PATIENTS AND METHODS

Trial Design
The trial design has been described previously. 10 Briefly, eligible patients had to be age Յ 75 years, be untreated previously for their prostate cancer, and had to have histologically proven prostate cancer, pathologic stage pT2-3, based on local pathology reports. They also had to present with at least one of the following risk factors for biochemical and local recurrence: extraprostatic extension of the tumor, positive surgical margins, and/or invasion of seminal vesicles (as assessed by the local pathologist). Radiotherapy began within 16 weeks after surgery, irrespective of the postoperative prostatespecific antigen (PSA) level. Informed consent (written or oral) was obtained from all patients in accordance with national laws. In each participating center the local/national ethics review committee approved the protocol. After undergoing radical prostatectomy, a total of 1,005 patients were randomly assigned to either the wait-and-see arm (n ϭ 503) or the intervention arm (n ϭ 502). Randomization was performed centrally by minimization algorithm after verification of all eligibility criteria with stratification for the treating institution, extraprostatic extension, positive margins, and seminal vesicle invasion. Irradiation started once patients had recovered from surgery and there were no major voiding problems. Postoperative irradiation consisted of 60 Gy administered with conventional techniques and delivered during 6 weeks, as described previously in more detail. 
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Follow-up of the participants of the trial consisted of digital rectal examination and PSA testing at 4, 8, and 12 months after surgery, then every 6 months until the end of the fifth year, then every year until death. Chest radiography and bone scans were done every year or if clinical or biochemical disease progression was suspected. Computed tomography scans and liver ultrasound were used for confirmation of suspected progression. In patients in the wait-and-see arm, subsequent treatment (radiotherapy or other) was delayed until biochemical or clinical failure; radiotherapy was the recommended treatment for local relapse.
The primary trial end point and end point of the present analysis is biochemical progression-free survival, defined as the time from random assignment until the day of first biochemical or clinical progression or start of treatment in the absence of progression, if any, or death as a result of any cause. Biochemical progression was defined as every increase above the lowest postoperative value to a value more than 0.2 ng/mL that was confirmed twice, at minimum 2-week intervals. Local recurrence had to be documented by a digital rectal examination (with or without biopsy) and distant relapse by sonography or radiographic or scintigraphic imaging.
Pathology of Prostatectomy Specimens
The total number of participants of this multi-institutional trial was 1,005, but for practical reasons only the prostatectomy specimens of 566 participants, included by the 11 major participating hospitals were reviewed. Fourteen patients were ineligible, leaving a total of 552 eligible patients (280 in the wait-and-see arm and 272 in the postoperative irradiation arm; Table 1 ). After formalin fixation, the prostatectomy specimens were totally embedded after inking the outer surface of the specimens using essentially the same protocol for sectioning in all participating hospitals. 13, 14 This includes separate embedding of parasagittal sections of the apex and bladder neck margin. Exclusion criteria for pathologic review were hormonal therapy before prostatectomy or incomplete embedding of the prostatectomy. The pathologic review was performed by a single pathologist with experience in urogenital pathology (T.H.V.d.K.) and included the examination of all slides of the radical prostatectomy specimen. In addition to Gleason score, pathologic stage (TNM, 1997), presence of extraprostatic extension, invasion of seminal vesicles, and surgical margin status were recorded. If extraprostatic extension was present, its extent (focal [ie, extending Ͻ 1 high power field] or otherwise extensive [ie, Ͼ 1 high power field]) and side of the extension were recorded. Extraprostatic extension was defined by either infiltration of the carcinoma of the prostatic pseudocapsule into the direct vicinity, beyond the adipose tissue, or within the neurovascular bundle beyond the outer contour of the adjacent pseudocapsule.
12 Bladder invasion was determined by invasion in the large bundles of smooth muscle, characteristic of the muscularis propria of the 
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www.jco.orgurinary bladder. Positive margin status was recorded when tumor cells were present within the inked margin. For positive surgical margin, apical and nonapical (designated as lateral) involvement was distinguished.
Statistics
Interactions between the magnitude of the treatment benefit and putative predictive factors were studied by means of the log-rank test for heterogeneity 15 and the effects of the predictive factors are represented on Forest plots. 16 The following factors were studied: seminal vesicle invasion, extraprostatic extension, surgical margin status and localization (apex, lateral, or both), and Gleason sum (Յ 6, 7, or Ͼ 7) assessed by the review pathologist, as well as the postprostatectomy PSA level (Յ 0.2 v Ͼ 0.2 ng/mL). Event-free rates were estimated by Kaplan-Meier. 17 The statistical significance level was set at .05.
RESULTS
Comparison of Patient Characteristics
The characteristics of the patients for whom review pathology is available are listed in Table 1 . All of these patients were treated in the hospitals that contributed most to the accrual. The patients whose specimens were reviewed centrally had a somewhat better prognosis than those whose specimens were not reviewed centrally (P ϭ .056). The 5-year biochemical progression-free survival rate was 59.9% (95% CI, 54.6% to 65.2%) for the nonreviewed patients compared with 65.8% (95% CI, 61.3% to 70.2%) for the reviewed group. The group excluded from analysis also exhibited some worse prognostic features (Table 1) , and more frequent positive margins and invasion of seminal vesicles by local pathology (P ϭ .0025 and P ϭ .0296, respectively).
Individual Predictive Factors for Benefit of Radiotherapy
We first assessed the interaction between each of the five considered factors and the magnitude of the benefit from radiotherapy in terms of biochemical progression-free survival (Fig 1) , and then repeated the analysis on the subset of patients with PSA Յ 0.2 ng/mL after surgery (Fig 2) .
Overall, there was no statistically significant predictive impact of postoperative PSA and Gleason sum or seminal vesicle invasion (P Ͼ .1 for each; Figs 1 and 2). The treatment benefit seemed larger in patients without extraprostatic extension (heterogeneity, P ϭ .02; Fig  1) when all patients were included in the analysis, but the effect was no longer statistically significant when the analysis was restricted to the patients whose PSA remained more than 0.2 ng/mL after surgery (P ϭ .06; Fig 2) .
Only surgical margin status caused a statistically significant interaction with the treatment effect (heterogeneity, P Ͻ .01) to such an extent that the treatment benefit in patients with negative margins is not significant (Figs 1 and 2 ; Table 2 ). Figure 3 displays the Kaplan and Meier curves for biochemical progression-free survival according to margin status and treatment arm: no difference is found between the patients with negative surgical margins in the control and irradiation arm (P Ͼ .1) and the patients with positive margins in the irradiation arm (P ϭ .070), whereas only those with positive margins in the control arm fare significantly worse (P ϭ .001). The 5-year biochemical progression-free survival rate was 67.4% (95% CI, 56.1% to 76.3%) and 76.2% (95% CI, 66.1% to 83.6%) for the patients with negative margins in the control and irradiation arm, respectively; it was 77.6% (95% CI, 68.8% to 84.2%) for the patients with positive margins in the irradiation arm but was 48.5% (95% CI, 39.6 to 58.9) for the patients with positive surgical margin in the control arm.
The hazard ratio for the treatment benefit in the group with negative surgical margins was 0.87 (95% CI, 0.53 to 1.46; P ϭ .601), based on 62 events, and it is 0.38 (95% CI, 0.26 to 0.54; P Ͻ .0001) in the group with positive surgical margins according to the review pathology. This means that for every 1,000 patients with negative margins, adjuvant irradiation would prevent biochemical relapse by year 5 in 88 patients, whereas irradiating 1,000 patients with positive margins would prevent relapse in 291 patients (P Ͻ .01). 
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Excluding the patients with PSA more than 0.2 ng/mL immediately after prostatectomy, the hazard ratio for irradiation was 1.11 (95% CI, 0.61 to 1.99; P ϭ .740) for the patients with negative margins and the hazard ratio was 0.29 (95% CI, 0.18 to 0.47; P Ͻ .0001) for the patients with positive margins.
Impact of Positive Margin Localization
Except for 28 of the 322 patients with a positive margin, the review pathologist could also classify the localization of the margin positivity: 65 patients had apically positive margin only, 168 had lateral positive margins, and 61 had both lateral and apical positive margins. The distribution was similar in both arms. Figures 4A and 4B show the forest plot of the treatment benefit according to the localization of the positive margins in all assessed patients and in the patients with postoperative PSA Յ 0.2 ng/mL. The two figures show that the magnitude of the treatment benefit does not differ significantly in function of the localization of the positive margin (heterogeneity, P Ͼ .1), although there is a trend for a larger benefit in the small group of patients with positive margins in both the apex and the lateral margins.
The biochemical progression-free survival by margin status and localization is shown in Figures 5A and 5B for the patients in the control arm and in the postoperative irradiation group: without postoperative irradiation, margin positivity is a strong indicator of poor prognosis (P ϭ .001), but this effect is no longer observed when patients are irradiated postoperatively. Of note, the 5-year biochemical progression-free survival rates in patients with negative surgical margin amounts to 64.4% (95% CI, 56.1% to 76.3%) in the control group and 76.2% (95% CI, 66.1% to 83.6%) in the group irradiated postoperatively. 
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DISCUSSION
Radical prostatectomy is an effective therapy for patients with localized low-grade (Gleason score 5 to 6) and intermediate-grade (Gleason score 7) prostate cancer, given that it is associated with excellent long-term prostate cancer-specific survival. 18, 19 The identification of positive surgical margins is declining in current populations, 20,21 but remains stable at approximately 25% to 35% of men with non-organconfined prostate cancers. 21, 22 This places them at risk for biochemical and clinical disease recurrence. 5 For this reason, several authors advocated the use of immediate postoperative radiotherapy for patients with adverse risk factors in their prostatectomy specimen to reduce the risk of local recurrence and subsequent distant metastasis.
9,24-28 Radiotherapy is believed to act by destroying residual carcinoma cells in the surgical wound bed, and therefore this therapy is believed to be particularly effective in patients with positive surgical margins. The effectiveness of radiotherapy in patients with negative margins but who carry any of the other adverse risk factors (ie, extraprostatic extension, seminal vesicle invasion, and/or high Gleason score) in their prostatectomy specimens remains uncertain.
Our subset analysis of these patients showed that adjuvant radiotherapy reduces the risk of biochemical recurrence specifically in those with positive surgical margins, whereas those with negative margins (irrespective of other risk factors) in general do not seem to benefit. Importantly, our data indicate that about three patients with positive margins need to be treated with adjuvant radiotherapy to prevent one biochemical recurrence. We emphasize here that this conclusion was only reached after a scrutinized central review of the prostatectomy specimens, whereas data from local pathology did not show this marked effect of surgical margin status on radiotherapy outcome. 10 Obviously, this variability in assessment of surgical margin status detracts from the generalized applicability of our findings. It was noted that the level of agreement between local and review pathology varied strongly for the different participating hospitals ( scores between 0.13 and 0.64), 12 which emphasizes the importance of the uniform application of well-established rules regarding the determination of margin status in prostatectomy specimens.
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The somewhat worse pathologic features, including positive margins and invasion of seminal vesicles, of the nonreviewed patient group as compared with the reviewed patients may have biased our results. However, in the population with available pathology review, the treatment benefit was strongest in the patients with adverse pathologic factors, including positive surgical margins, and therefore it is likely that our conclusions remain valid for the entire population.
It is conceivable that additional adverse factors related to development of biochemical and clinical recurrence, such as high Gleason score and seminal vesicle involvement, 30,31 may have negated the effect of adjuvant radiotherapy as a result of their association with an increased risk of distant metastasis. 32 This would suggest that the postoperative irradiation is not able to prevent the occurrence of metastasis any longer, given that the systemic dissemination of tumor cells already has occurred before therapy in these patients. However, a few studies on relatively small series of patients showed a beneficial effect of postoperative radiotherapy for biochemical recurrence in patients with invasion of their seminal vesicles.
28,33 These retrospective studies were compromised by the presence of an excess of other risk factors in the patients who did not receive radiotherapy and by hormonal manipulation. In our study, Gleason score continued to be a powerful prognosticator for biochemical progression in the radiotherapy arm, but we noted that a beneficial effect was obtained in patients with positive surgical margins, both for high Gleason score prostate cancers and those with seminal vesicle invasion (Fig 5) . However, our data suggest that the latter subset of patients with both positive margins and seminal vesicle invasion may have less benefit of adjuvant radiotherapy compared with the entire group of patients with positive surgical margins.
Prostate cancer differs from most other malignancies because of its slowly developing nature: nonradical resection of prostate cancer is not always followed by rapid biochemical recurrence; likewise, a local recurrence does not necessarily evolve toward systemic spread and death as a result of the disease. A biochemical recurrence is reported in approximately 30% to 75% of patients with positive surgical margins. 5, 20, 21 The strong variation reported in literature is likely due to additional factors such as Gleason score distribution and stage distribution of the patients under study, as well as interobserver variation for determination of margin status. It has also been noted that the majority of patients with biochemical recurrence will not develop a local recurrence or distant disease, 21,34 and biochemical progression is by some considered a poor surrogate marker for disease progression. 35, 36 Local growth can lead to anxiety of the patient and to additional treatment.
Some studies claimed that apex positivity is less likely to result in biochemical or local recurrence, 37,38 but this was not substantiated by other series 21,30,39,40 and also not in our patient group. In addition, we did not show a difference in treatment benefit for patients with only apex positivity as compared with those with positive lateral margins. Those with both apex and lateral margin positivity seemed to benefit more than those with positivity at one of the sites, emphasizing the predictive impact of positive surgical margins. Unfortunately, we were not able to perform subgroup analysis for actual clinical recurrence of disease, given that the number of events was too small. Some controversy exists in the literature with regard to the clinical significance of surgical margin status as the sole adverse risk factor. Although most but not all studies have shown that positive surgical margin status represents an independent risk factor for biochemical recurrence, in addition to Gleason sum, preoperative PSA, and pathologic stage, 5, 21 it is not certain that positive surgical margins add to the risk of actual local recurrence or systemic disease. Those few studies reporting on prognosticators for clinical recurrence so far failed to demonstrate any independent prognostic impact of surgical margin status, 3, 21 but their relative short follow-up periods may have contributed to these negative findings. In a similar vein, it remains uncertain to what extent prostate cancer-specific or metastases-free survival of the various subsets of patients with positive margins will be influenced by adjuvant radiotherapy. These pertinent questions may be solved when longer follow-up data of the participants of our trial EORTC 22911 become available.
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